Goldman Sachs’s Standard BioTools LAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $867K | Buy |
943,185
+417,130
| +79% | +$505K | ﹤0.01% | 5192 |
|
|
2025
Q4 | $673K | Sell |
526,055
-769,911
| -59% | -$1.03M | ﹤0.01% | 5416 |
|
|
2025
Q3 | $1.68M | Sell |
1,295,966
-23,118
| -2% | -$30.3K | ﹤0.01% | 4625 |
|
|
2025
Q2 | $1.58M | Buy |
1,319,084
+642,555
| +95% | +$712K | ﹤0.01% | 4358 |
|
|
2025
Q1 | $731K | Sell |
676,529
-496,941
| -42% | -$698K | ﹤0.01% | 4928 |
|
|
2024
Q4 | $2.05M | Buy |
1,173,470
+254,928
| +28% | +$475K | ﹤0.01% | 4259 |
|
|
2024
Q3 | $1.77M | Buy |
918,542
+277,559
| +43% | +$544K | ﹤0.01% | 4256 |
|
|
2024
Q2 | $1.13M | Sell |
640,983
-2,636,730
| -80% | -$6.44M | ﹤0.01% | 4350 |
|
|
2024
Q1 | $8.88M | Buy |
3,277,713
+3,144,153
| +2,354% | +$7.59M | ﹤0.01% | 2580 |
|
|
2023
Q4 | $295K | Buy |
+133,560
| New | +$285K | ﹤0.01% | 5015 |
|
|
2023
Q1 | – | Sell |
-45,273
| Closed | -$53K | – | 6099 |
|
|
2022
Q4 | $53K | Sell |
45,273
-996
| -2% | -$1.23K | ﹤0.01% | 5588 |
|
|
2022
Q3 | $51K | Sell |
46,269
-193,841
| -81% | -$293K | ﹤0.01% | 5799 |
|
|
2022
Q2 | $385K | Buy |
240,110
+80,849
| +51% | +$200K | ﹤0.01% | 5267 |
|
|
2022
Q1 | $572K | Sell |
159,261
-174,365
| -52% | -$602K | ﹤0.01% | 5229 |
|
|
2021
Q4 | $1.31M | Sell |
333,626
-43,927
| -12% | -$206K | ﹤0.01% | 4620 |
|
|
2021
Q3 | $2.49M | Buy |
377,553
+75,882
| +25% | +$499K | ﹤0.01% | 3982 |
|
|
2021
Q2 | $1.86M | Sell |
301,671
-45,552
| -13% | -$244K | ﹤0.01% | 4276 |
|
|
2021
Q1 | $1.57M | Sell |
347,223
-158,025
| -31% | -$868K | ﹤0.01% | 4229 |
|
|
2020
Q4 | $3.03M | Buy |
505,248
+403,091
| +395% | +$2.65M | ﹤0.01% | 3409 |
|
|
2020
Q3 | $759K | Sell |
102,157
-661,697
| -87% | -$4.57M | ﹤0.01% | 4257 |
|
|
2020
Q2 | $3.06M | Buy |
763,854
+411,507
| +117% | +$1.43M | ﹤0.01% | 3151 |
|
|
2020
Q1 | $895K | Buy |
352,347
+124,451
| +55% | +$409K | ﹤0.01% | 3832 |
|
|
2019
Q4 | $793K | Sell |
227,896
-203,081
| -47% | -$714K | ﹤0.01% | 4260 |
|
|
2019
Q3 | $2M | Buy |
430,977
+126,425
| +42% | +$996K | ﹤0.01% | 3533 |
|
|
2019
Q2 | $3.75M | Buy |
304,552
+85,309
| +39% | +$1.09M | ﹤0.01% | 3057 |
|
|
2019
Q1 | $2.91M | Buy |
219,243
+180,130
| +461% | +$1.9M | ﹤0.01% | 3352 |
|
|
2018
Q4 | $338K | Sell |
39,113
-18,384
| -32% | -$143K | ﹤0.01% | 4575 |
|
|
2018
Q3 | $430K | Buy |
57,497
+4,593
| +9% | +$32.7K | ﹤0.01% | 4497 |
|
|
2018
Q2 | $315K | Sell |
52,904
-142,637
| -73% | -$813K | ﹤0.01% | 4757 |
|
|
2018
Q1 | $1.14M | Sell |
195,541
-9,713
| -5% | -$63.8K | ﹤0.01% | 3970 |
|
|
2017
Q4 | $1.21M | Sell |
205,254
-11,488
| -5% | -$62.9K | ﹤0.01% | 4185 |
|
|
2017
Q3 | $1.09M | Buy |
216,742
+71,396
| +49% | +$300K | ﹤0.01% | 4502 |
|
|
2017
Q2 | $587K | Buy |
145,346
+283
| +0.2% | +$1.34K | ﹤0.01% | 4952 |
|
|
2017
Q1 | $825K | Sell |
145,063
-603
| -0.4% | -$3.82K | ﹤0.01% | 4556 |
|
|
2016
Q4 | $1.06M | Buy |
145,666
+5,848
| +4% | +$36.7K | ﹤0.01% | 4399 |
|
|
2016
Q3 | $1.12M | Buy |
139,818
+10,425
| +8% | +$95.7K | ﹤0.01% | 4302 |
|
|
2016
Q2 | $1.17M | Buy |
129,393
+109,847
| +562% | +$1.03M | ﹤0.01% | 4064 |
|
|
2016
Q1 | $158K | Sell |
19,546
-606,616
| -97% | -$4.37M | ﹤0.01% | 5798 |
|
|
2015
Q4 | $6.77M | Buy |
626,162
+160,175
| +34% | +$1.57M | ﹤0.01% | 2563 |
|
|
2015
Q3 | $3.78M | Buy |
+465,987
| New | +$7.33M | ﹤0.01% | 3144 |
|
|
2015
Q2 | – | Sell |
-15,574
| Closed | -$656K | – | 7349 |
|
|
2015
Q1 | $656K | Sell |
15,574
-18,114
| -54% | -$716K | ﹤0.01% | 4867 |
|
|
2014
Q4 | $1.14M | Buy |
33,688
+17,218
| +105% | +$488K | ﹤0.01% | 4423 |
|
|
2014
Q3 | $404K | Sell |
16,470
-35,077
| -68% | -$986K | ﹤0.01% | 5467 |
|
|
2014
Q2 | $1.51M | Buy |
51,547
+2,504
| +5% | +$80.2K | ﹤0.01% | 4288 |
|
|
2014
Q1 | $2.16M | Buy |
49,043
+1,793
| +4% | +$78.9K | ﹤0.01% | 3902 |
|
|
2013
Q4 | $1.81M | Buy |
47,250
+14,791
| +46% | +$436K | ﹤0.01% | 4181 |
|
|
2013
Q3 | $712K | Buy |
+32,459
| New | +$638K | ﹤0.01% | 4868 |
|
Other funds holding LAB
CC
MCO
LFCM
VCM
HBWM
Goldman Sachs's LAB Position: Q1 2026 in Review
Goldman Sachs increased its Standard BioTools (LAB) stake by 79% in Q1 2026, buying an estimated $505K and bringing the position to 943,185 shares worth $867K. The position accounts for ﹤0.01% of the portfolio, ranked #5192.
Goldman Sachs first reported a position in LAB in Q3 2013 and has held it in 47 quarters since. The position peaked at $8.88M in Q1 2024. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.
- Goldman Sachs held 943,185 shares of Standard BioTools worth $867K as of Q1 2026.
- Goldman Sachs bought 417,130 Standard BioTools shares in Q1 2026, an estimated $505K.
- Standard BioTools made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5192 holding.
- Goldman Sachs first reported a position in Standard BioTools in Q3 2013 and has held it in 47 quarters since.
- Goldman Sachs's Standard BioTools position peaked at $8.88M in Q1 2024.
- 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.